RJA
IART icon

Ross\Johnson & Associates’s Integra LifeSciences IART Stock Holding History

Ross\Johnson & Associates’s Portfolio IART Stock Details IART Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-5
Closed -$62 – 278
2025
Q4 		$62 Buy
+5
New +$66 ﹤0.01% 340

Other funds holding IART

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
PCMI
Paradigm Capital Management Inc Albany, New York $2.61B AUM 78.58% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Ross\Johnson & Associates's IART Position: Q1 2026 in Review

Ross\Johnson & Associates sold out of Integra LifeSciences (IART) in Q1 2026, closing a stake of 5 shares — an estimated $62 sold.

Ross\Johnson & Associates first reported a position in IART in Q4 2025 and held it in 1 quarter. The position peaked at $62 in Q4 2025. 201 funds tracked by Wall St. Rank hold IART as of Q1 2026.

  • Ross\Johnson & Associates reported no remaining Integra LifeSciences position as of Q1 2026 after selling out during the quarter.
  • Ross\Johnson & Associates sold 5 Integra LifeSciences shares in Q1 2026, an estimated $62.
  • Ross\Johnson & Associates first reported a position in Integra LifeSciences in Q4 2025 and held it in 1 quarter.
  • Ross\Johnson & Associates's Integra LifeSciences position peaked at $62 in Q4 2025.
  • 201 funds tracked by Wall St. Rank held Integra LifeSciences as of Q1 2026.

Based on Ross\Johnson & Associates's 13F filing for Q1 2026, filed 8 May 2026.